Newly diagnosed multiple myeloma (MM) patients requiring salvage therapy prior to high dose therapy (HDT) have equivalent progression free survival and overall survival to those receiving a single induction regimen

被引：0
|
作者：
Percy, L. A. [1 ]
Rabin, N. [1 ]
Qian, W. [2 ]
Moore, S. [1 ]
Symeonidis, A. [3 ]
Dorman, J. [1 ]
Quinn, J. [1 ]
Ings, S. [1 ]
Watts, M. [1 ]
Linch, D. [1 ]
Yong, K. [1 ]
机构：
[1] Univ Coll London Hosp, Dept Haematol, London, England
[2] MRC Clin Trials Unit, London, England
[3] Univ Patras, Sch Med, Dept Haematol, GR-26110 Patras, Greece
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2010年 / 149卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
99
引用
收藏
页码：42 / 42
页数：1
相关论文
共 50 条
  • [41] Progression free survival in patients with Multiple Myeloma treated with induction therapy followed by Autologous Stem Cell Transplant 5 years experience
    Plaza Meneses, C.
    Villaescusa de la Rosa, T.
    Lopez Lorenzo, J. L.
    Teran Benzaquen, C.
    Sanchez Fernandez, M. S.
    Prieto Pareja, E.
    Askari, E.
    Velasco Valdazo, A.
    Llamas Sillero, P.
    BONE MARROW TRANSPLANTATION, 2016, 51 : S305 - S306
  • [42] Thalidomide Combined With High Dose Melphalan Improves Event Free and Overall Survival In Patients With Newly Diagnosed Multiple Myeloma: Extended Follow-Up Of The HOVON-50 Trial
    Lokhorst, Henk
    van der Holt, Bronno
    Zweegman, Sonja
    Vellenga, Edo
    Croockewit, Sandra
    Van Oers, Marinus N. J.
    von dem Borne, Peter
    Wijermans, Pierre W.
    Schaafsma, M. R.
    de Weerdt, Okke
    Wittebol, Shulamiet
    Delforge, Michel
    Bos, Gerard M. J.
    Sinnige, Harm
    MarwijkKooy, Marinus
    Joosten, Peter
    Minnema, Monique C.
    Ammerlaan, Rianne
    Sonneveld, Pieter
    BLOOD, 2013, 122 (21)
  • [43] Receiving four or less cycles of therapy predicts poor survival in newly diagnosed transplant ineligible patients with myeloma who are treated with bortezomib-based induction
    Mollee, Peter
    Boyle, Stephen
    Wellard, Cameron
    Moore, Elizabeth
    Blacklock, Hilary
    Harrison, Simon J.
    Ho, P. Joy
    Hocking, Jay
    McQuilten, Zoe
    Quach, Hang
    Spearing, Ruth
    Wood, Erica
    Spencer, Andrew
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E233 - E234
  • [44] Total therapy 2 (TT 2) for newly diagnosed patients with multiple myeloma (MM): Examination of dose effect of thalidomide (T) among those randomized to T.
    Thertulien, R
    Barlogie, B
    Zangari, M
    Fassas, A
    Stover, J
    Milner, T
    Rasmussen, E
    Anaissie, E
    Lee, CK
    Hollmig, K
    Talamo, G
    Tricot, G
    BLOOD, 2004, 104 (11) : 268A - 268A
  • [45] Early versus delayed autologous stem cell transplant (ASCT) in patients receiving induction therapy with lenalidomide, bortezomib, and dexamethasone (RVD) for newly diagnosed multiple myeloma (MM)
    Nooka, Ajay K.
    Langston, Amelia A.
    Waller, Edmund K.
    Heffner, Leonard T.
    Gleason, Charise
    Muppidi, Samatha
    Watson, Melanie
    Casbourne, Daniela
    Boise, Lawrence
    Kaufman, Jonathan L.
    Lonial, Sagar
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [46] Duration of Therapy Is Independently Associated with Improved Progression Free and Overall Survival Following First Line Therapy for Non-Transplant Eligible Patients with Multiple Myeloma: Retrospective Analysis from a Single Centre
    De-Silva, Dunnya
    Bloomfield, Adam
    Counsell, Nicholas
    Cheesman, Simon
    Rismani, Ali
    Rabin, Neil
    D'Sa, Shirley
    Kyriakou, Charalampia
    Galinsky, Jayne
    Richard, Sarah
    Popat, Rakesh
    Mehta, Atul
    Yong, Kwee L.
    BLOOD, 2016, 128 (22)
  • [47] Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant-ineligible patients with myeloma who are treated with bortezomib-based induction
    Boyle, Stephen
    Wellard, Cameron
    Moore, Elizabeth M.
    Blacklock, Hilary
    Harrison, Simon J.
    Ho, Phoebe Joy
    Hocking, Jay
    McQuilten, Zoe K.
    Quach, Hang
    Spearing, Ruth
    Wood, Erica M.
    Spencer, Andrew
    Mollee, Peter
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2021, 107 (04) : 497 - 499
  • [48] Neutrophil to lymphocyte ratio (NLR) impact on the progression-free survival and overall survival of multiple myeloma patients treated with high-dose chemotherapy and autologous stem cell transplantation
    Mikulski, Damian
    Koscielny, Kacper
    Nowicki, Mateusz
    Wawrzyniak, Ewa
    Kalwas, Marta
    Kowalik, Monika
    Pryt, Mateusz
    Seczkowska, Emilia
    Swiatek, Agnieszka
    Wierzbowska, Agnieszka
    Fendler, Wojciech
    LEUKEMIA & LYMPHOMA, 2023, 64 (01) : 98 - 106
  • [49] Impact of autologous stem cell transplantation (ASCT) on progression free survival (PFS) in newly diagnosed multiple myeloma patients (NDMM) with high risk cytogenetic abnormalities
    Guman, Tomas
    Sykora, Jan
    BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY, 2024, 125 (01): : 9 - 11
  • [50] RESPONSE AND SURVIVAL IMPROVEMENT WITH AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: DIFFERENT INDUCTION THERAPY IMPACT OVER THE LAST 30 YEARS
    Mateos Perez, Jose Miguel
    Fernandez-Aviles, Francesc
    Fernandez de larrea, Carlos
    Teresa Cibeira, Maria
    Tovar, Natalia
    Martinez, Carmen
    Gerardo Rodrigez-Lobato, Luis
    Suarez-Lledo, Maria
    Queralt Salas, Maria
    Rovira, Montserrat
    Blade, Joan
    Rosinol, Laura
    BONE MARROW TRANSPLANTATION, 2024, 59 : 515 - 516
12345